The questionnaire, called the “Functional Assessment of Cancer Therapy-Radionuclide Therapy,” is a 15-question survey that prompts patients to report on the symptoms and side effects associated with prostate cancer therapies called radionuclide therapy.
The questionnaire will help clinicians and patients better understand how cancer and its treatment can affect their quality of life, according to a Jan. 19 news release from the organization.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
